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  18 
This work describes the isolation, characterization, and identification by RP-HPLC-ESI-19 
Q-TOF of novel peptides that interfere in the fat digestion and absorption mechanisms 20 
by multiple pathways. Peptides were ultrafiltrated and peptides in the most active 21 
fraction were further separated by semipreparative RP-HPLC. Nine different 22 
subfractions were obtained observing a high amount of peptides in subfraction F3. 23 
Peptides in subfraction F3 could simultaneously reduce the solubility of cholesterol in 24 
micelles and inhibit pancreatic cholesterol esterase and pancreatic lipase, even after a 25 
simulated gastrointestinal digestion. The identification of lipid-lowering peptides has 26 
been scarcely performed and when done, low selectivity or sensitivity of employed 27 
identification techniques or conditions did not yield reliable results. Separation and 28 
detection of peptides by RP-HPLC-ESI-Q-TOF-MS was optimized and most favorable 29 
conditions were employed for the identification of peptides using de novo sequencing. 30 
Ten different peptides with 4-9 amino acids were identified. Main feature of identified 31 
peptides was the high acidity derived from a high presence of amino acids glutamic acid 32 
and aspartic acid in their sequences.  33 
 34 





































































1. Introduction 37 
 Hypercholesterolemia and hyperglycemia are metabolic disorders characterized 38 
by high levels of cholesterol and triglycerides in blood. Hyperlipidemia has increased 39 
worldwide due to the popularity of high-fat diets and non healthy lifestyles (Jacobson, 40 
Miller, & Schaefer, 2007).
 
Prevalence of hyperlipidemia is a risk factor in 41 
cardiovascular diseases such as coronary heart disease and atherosclerosis. Different 42 
synthetic drugs for treating this disease have been developed such as inhibitors of 43 
cholesterol endogenous synthesis, inhibitors of membrane proteins that promote the 44 
intestinal absorption of cholesterol, bile acid sequestrants, etc (Descamps, De Sutter, 45 
Guillaume, & Missault, 2011).
 
Nevertheless, diverse side effects (increase of hepatic 46 
transaminases and creatine kinase, muscle weakness, headache, sleep disorders, etc.) 47 
have been described derived from the long-term consumption of these synthetic drugs 48 
(Heidrich, Contos, Hunsaker, Deck, & Vander Jagt, 2004). Moreover, these synthetic 49 
drugs are usually limited to fight hyperlipidemia by following a single mechanism. 50 
Therefore, and especially in cases where cholesterol and triglycerides levels are 51 
moderate, the consumption of foods that contain or are enriched with lipid-lowering 52 
substances is advisable. 53 
 Bioactive peptides are natural molecules that have demonstrated a wide range of 54 
activities although hypolipidemic peptides have been much less reported than others. 55 
Peptides with capacity to reduce cholesterol and/or triglyceride levels have been 56 
obtained from different foods (Alhaj, Kanekanian, Peters, & Tatham, 2010; Rho, Park, 57 
Ahn, Shin, & Lee, 2007; Zhang, Yokoyama, & Zhang, 2012; Yust, Millán-Linares, 58 
Alcaide-Hidalgo, Milán, & Pedroche, 2012; Lammi et al., 2016; Marques, Fontanari, 59 
Pimenta, Soares-Freitas, & Areas, 2015; Liyanage et al., 2010). In addition to these 60 




































































of bioactive peptides although, again, not much attention has been paid to 62 
hypolipidemic peptides (García, Orellana, & Marina, 2016). Nakade et al. (2009) 63 
described the hypocholesterolemic capacity of a protein hydrolysate obtained from a 64 
meat industry byproduct that enabled the reduction of the micellar cholesterol solubility, 65 
the suppression of the cholesterol uptake by Caco-2 cells, and the cholesterol reduction 66 
in the serum of rats fed with the hydrolysate.
 
More recently, our research group has 67 
published a work describing antihypertensive, antioxidant, and hypocholesterolemic 68 
activities in seed hydrolysates obtained from Prunus genus fruits and olives. We 69 
observed that the hydrolysate obtained with Alcalase enzyme from the Picual olive 70 
seeds showed a high capability to reduce micellar cholesterol solubility (García, 71 
González-García, Vásquez-Villanueva, & Marina, 2016). Nevertheless, further studies 72 
are required to confirm these first results and to characterize these peptides.  73 
 Identification of peptides and proteins is mainly performed using reversed-phase 74 
(RP)-HPLC coupled to tandem mass spectrometry. Despite there is a wide bibliography 75 
devoted to the characterization and identification of bioactive peptides (García, 76 
Orellana, & Marina, 2016), a few works have been addressed in the case of lipid-77 
lowering peptides. Moreover, in most cases no peptide identification was carried out or 78 
only amino acid composition was detailed (Zhang, Yokoyama, & Zhang, 2012). The 79 
first identification of an hypolipidemic peptide was carried out using a protein 80 
sequencer which enabled to identify the peptide IIAEK in bovine milk -lactoglobulin 81 
(Nagaoka, 2001). Few years later, Zhong et al. (2007) could identify the hypolipidemic 82 
peptide WGAPSL in soy using RP-HPLC-MS. Alhaj et al. (2010) used RP-HPLC-83 
MS/MS with mobile phases containing 0.1% (v/v) trifluoroacetic acid (TFA) for the 84 
detection of peptides with hypocholesterolemic activity but, as expected, no sequencing 85 




































































workers (2015) also identified hypocholesterolemic peptides from cowpea using RP-87 
HPLC-MS/MS but reliability of data is questioned since only peptides with ALC 88 
between 50-80% were identified.  89 
 The aim of this work was  to evaluate the capacity of olive seed peptides to 90 
reduce the amount of exogenous cholesterol and triglycerides, to isolate peptides with 91 
lipid-lowering capacity from the olive seed, and to optimize a RP-HPLC-tandem mass 92 






































































2. Materials and methods 96 
2.1 Chemical and samples 97 
 All chemicals and reagents were of analytical grade. Water was daily obtained 98 
from a Milli-Q system from Millipore (Bedford, MA, USA). Supergradient HPLC grade 99 
acetonitrile (ACN), acetic acid (AA), acetone, methanol (MeOH), and hexane were 100 
purchased from Scharlau Chemie (Barcelona, Spain). Tris (hydroxymethyl) 101 
aminomethane (Tris), hydrochloric acid (HCl), sodium dihydrogen phosphate, di- 102 
sodium tetraborate, and sodium dodecyl sulphate (SDS) were from Merck (Darmstadt, 103 
Germany). Sodium hydroxide, dithiothreitol (DTT), trifluoroacetic acid (TFA), bovine 104 
pancreatic cholesterol esterase, porcine pancreatic lipase, p-nitrophenylbutylrate (p-105 
NPB), p-nitrophenylpalmitate (p-NPP), taurocholic acid, taurodeoxycholic acid, 106 
glycodeoxycholic acid, oleic acid, phosphatidylcholine, simvastatin, rutin trihydrate, 107 
cholestyramine, β-sitosterol, o-phthaldialdehyde (OPA), L-glutathione (GSH), pepsin, 108 
pancreatin, taurocholate, cholesterol, β-mercaptoethanol, sodium chloride (NaCl), 3-109 
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 110 
(DMSO), Dulbecco's modified eagle's medium (DMEM), antibiotics (penicillin, 111 
streptomycin, and amphotericin), fetal bovine serum, and phosphate buffered (PB) were 112 
all from Sigma-Aldrich (Saint Louis, MO, USA). Cholesterol oxidase kit was purchased 113 
from BioAssay Systems (Hayward, CA, USA). Total bile acid kit was from Bio-Quant 114 
(San Diego, CA, USA). Alcalase 2.4 L FG, produced by fermentation of a selected 115 
strain of Bacillus licheniformis, mainly composed by Subtilisin A, with catalytic activity 116 
on serine, and with an activity of 2.4 Anson units per gram, was kindly donated by 117 
Novozymes Spain S.A. (Madrid, Spain). All cell lines (HeLa, HT-29, and HK-2) were 118 




































































of ‘Manzanilla’ variety were kindly donated by the olive company FAROLIVA S.L. 120 
(Murcia, Spain). 121 
2.2. Peptide production 122 
 Olive stones were crushed to release the seed and seeds were ground in a 123 
domestic mill. Olive seeds were defatted with hexane for 30 min (four times). 124 
Extraction of proteins from defatted olive seeds was performed following the method 125 
developed by Esteve et al. (2010). Briefly, 0.03 g of milled and defatted olive seeds 126 
were treated with 5 mL of an extracting buffer (100 mM Tris-HCl (pH 7.5), 0.5% (w/v) 127 
SDS, 0.5% (w/v) DTT) using a high intensity focused ultrasound (HIFU) probe (model 128 
VCX130, Sonic Vibra-Cell, Hartford, CT, USA) at 30% of amplitude for 5 min. After 129 
centrifugation (4000g, 10 min), proteins in the supernatant were precipitated with cold 130 
acetone (10 mL) in the fridge for 24 h, followed by centrifugation and drying at room 131 
temperature to obtain a protein isolate. The protein isolate was dissolved in a 5 mM 132 
borate buffer (pH 8.5) and hydrolyzed with Alcalase (0.15 UA/ g protein) by incubation 133 
in the Thermomixer Compact (Eppendorf, Hamburg, Germany) at 50 ºC during 4 h. The 134 
digestion was stopped by increasing the temperature to 100 ºC for 10 min and 135 
centrifuging for 10 min at 6000g. Finally, the supernatant, containing peptides, was 136 
stored at – 20 ºC. 137 
2.3. Semipreparative RP-HPLC fractionation  138 
 The hydrolysate solution was firstly fractionated by ultrafiltration using 139 
molecular weight (Mw) cut-off filters Amicon® Ultra of 5 kDa and 3 kDa from Merck 140 
Millipore (Tullagreen, Ireland) to obtain three fractions: a fraction with peptides bigger 141 
than 5 kDa, a fraction with peptides with Mw between 5 and 3 kDa, and a fraction with 142 




































































 Peptide separation by RP-HPLC was performed using a HPLC equipment from 144 
Agilent Technologies (Pittsburgh, PA, USA) model 1100, equipped with a vacuum 145 
degasser, a quaternary pump, an automatic injection system, a thermostatic column 146 
compartment, a diode array detector, and a fluorescence detector. Control of the 147 
equipment and data acquisition were performed with the HP ChemStation software. The 148 
separation was carried out in an Jupiter 4u Proteo (250 x 10 mm id) from Phenomenex 149 
(Torrance, CA, USA). Peptides were separated using an elution gradient from 25-54% 150 
B in 45 min, where mobile phase A was water with 0.1% (v/v) TFA and mobile phase B 151 
was ACN with 0.1% (v/v) TFA. Other conditions were: flow-rate, 1 mL/min; 152 
temperature, 25 ºC; injection volume, 600 μL; fluorescence detection at λexc = 280 nm 153 
and λem = 360 nm. Sample was injected two times and nine fractions (F1-F9) were 154 
collected at 5 min intervals in every injection. Every fraction was evaporated using a 155 
centrifugal evaporator (Eppendorf, Hamburg, Germany) and the remaining pellet was 156 
dissolved in 600 µL of digestion buffer (5 mM borate buffer, pH 8.5). Solutions 157 
corresponding to every fraction, injected two times, were pooled and used for future 158 
analysis. 159 
2.4. Peptide content 160 
 The content of peptides was determined according to the method described by 161 
Wang et al. (2008) with some modifications. A 40 mg/mL solution of OPA reagent in 162 
MeOH was employed to prepare a fresh 5 mL mixture consisting of 2.5 mL of 100 mM 163 
disodium tetraborate, 1.0 mL of 5% (v/v) SDS, 1.39 mL of water, 10 μL of β-164 
mercaptoethanol, and 100 μL of previous OPA solution. Next, 2.5 μL of sample was 165 
incubated with 100 μL of that mixture for 8 min at room temperature and the 166 
absorbance corresponding to the compounds formed by the reaction of OPA reagent 167 




































































Lambda 35 from Perkin-Elmer (Waltham, MA, USA). The peptide content was 169 
calculated by interpolation in a calibration curve obtained when using the tripeptide 170 
GSH (0–5 mg/ mL) as standard.  171 
2.5. Evaluation of hypolipidemic activity of peptides 172 
 Hypolipidemic activity of hydrolysates and fractions was evaluated using four 173 
different in vitro assays to measure the ability of peptides to reduce absorption of 174 
dietary cholesterol (ability to reduce micellar cholesterol solubility, to inhibit the 175 
activity of pancreatic cholesterol esterase and to bind bile acids) and triglycerides 176 
(ability to inhibit the activity of pancreatic lipase). In every determination, three 177 
replicates were measured by triplicate. 178 
2.5.1. Evaluation of the capacity to reduce the micellar cholesterol solubility 179 
 Cholesterol is solubilised in micelles for its transportation and absorption and the 180 
displacement of cholesterol in the micelle results in a decrease of cholesterol adsorption 181 





with minor modifications. Briefly, a solution containing 0.5 mM cholesterol, 183 
1 mM oleic acid, and 2.4 mM phosphatidylcholine in MeOH was prepared and dried 184 
before the addition of a 15 mM PB (pH 7.4) containing 6.6 mM taurocholate salt and 185 
132 mM NaCl. This solution was sonicated for 1 min at 95% with the HIFU probe and 186 
incubated overnight at 37 ºC. After preparation of micelles, 150 μL of peptide or 187 
controls were added to 50 μL of the micelle solution, sonicated (1 min at 95%), and 188 
incubated in the Thermomixer for 2 h at 37 ºC. The mixture was then centrifuged for 10 189 
min at 6000g. The supernatant was collected for the determination of the cholesterol 190 
remaining in micelles using a cholesterol kit. Determination of cholesterol consisted of 191 




































































resulting cholesterol to its ketone form and hydrogen peroxide by cholesterol oxidase 193 
enzyme, and detection of resulting hydrogen peroxide by its reaction with 10-acetyl-3,7-194 
dihydroxyphenoxazine to obtain a product which absorbs at 570 nm. Cholestyramine 195 
was used as positive control. The reduction in the micellar solubility of cholesterol was 196 
calculated using the following equation: 197 
 198 
where Co is the initial concentration of cholesterol in micelles (without peptides) and Cs 199 
is the concentration of cholesterol in micelles when adding peptides or positive control. 200 
2.5.2. Evaluation of the capacity to inhibit pancreatic cholesterol esterase enzyme 201 
 The inhibition of the pancreatic cholesterol esterase enzyme, that hydrolyzes 202 
dietary cholesterol ester into free cholesterol, decreases the bioavailability of dietary 203 
cholesterol esters in animals (Krause, Sliskovic, Anderson, & Homan, 1998).
 
This assay 204 
was carried out following the method described by Pietsch & Gütschow (2005). 205 
Peptides were incubated with 6 mM taurocholic acid and 20 mM p-NPB in 100 mM PB 206 
(pH 7.0) containing 100 mM NaCl at 25 ºC. The reaction was initiated by adding 207 
porcine pancreatic cholesterol esterase (25 μg/mL). After incubation for 5 min at room 208 
temperature, the absorbance corresponding to p-nitrophenol, obtained by the hydrolysis 209 
of p-NPB, was measured at 405 nm. Simvastatin was employed as positive control. The 210 
percentage of inhibition of the pancreatic cholesterol esterase enzyme was calculated 211 





































































where AMáx is the absorbance obtained under conditions of maximum enzyme activity 214 
(without peptides), AS is the absorbance obtained in presence of peptides/positive 215 
control and ASo is the absorbance obtained when no enzyme was added. 216 
2.5.3. Evaluation of the capacity to bind bile acids 217 
 Bile acids are synthesized in the liver by oxidation of endogenous cholesterol. 218 
Sequestering of bile acids results in the reduction of the bile acid pool which produces a 219 
greater conversion of endogenous cholesterol into bile acids and a decreased plasma 220 
cholesterol level (Insull, 2006). This assay was performed following the method 221 
described by Yoshie-Stark & Wäsche (2004). Three different biles acids were 222 
employed: taurocholic acid, glycodeoxycholic acid, and taurodeoxycholic acid. Briefly, 223 
peptides were incubated in the Thermomixer with every bile acid (2 mM) in 0.1 M PB 224 
(pH 7.0) containing 0.1 M NaCl at 37 ºC for 90 min. The mixture was centrifuged (10 225 
min, 6000g) and the supernatant was collected. The precipitate was washed with 1 mL 226 
of PB and centrifuged again and the supernatant was collected and combined with 227 
earlier supernatant. The pooled supernatant was frozen at 20 ºC until analysis. The 228 
amount of bile acids was determined using a total bile acid kit. The assay is based on an 229 
reaction driven by 3α-hydroxysteroid dehydrogenase enzyme in which bile acids are 230 
incubated in the presence of NADH and thio-NAD
+
. Under these conditions, thio-NAD
+ 231 
is converted to its reduced form thio-NADH which is detected at 630 nm. β-sitosterol 232 
was used as positive control. The percentage of binding to bile acids was calculated 233 
using the following equation: 234 
 235 
where Co is the initial concentration of bile acids in control (without peptides) and Cs is 236 




































































2.5.4. Evaluation of the capacity to inhibit pancreatic lipase enzyme 238 
 Absorption of triglycerides can be ameliorated by the inhibition of pancreatic 239 
lipase enzyme that is responsible for their hydrolysis into monoglycerides and free fatty 240 
acids (Mattson & Beck, 1955). Based on a method previously published 241 
(Adisakwattana, 2010), peptides were incubated with 0.06 mg/ mL of porcine pancreatic 242 
lipase and 3.33 mM of p-NPP in 100 mM Tris-HCl buffer (pH 8.5) at 37 ºC for 25 min 243 
in the Thermomixer. The absorbance of released p-nitrophenol was measured at 405 244 
nm. Rutin was used as positive control. Percentage of inhibition of pancreatic lipase was 245 
determined by the following equation: 246 
 247 
where AMáx is the absorbance obtained when no peptides were added (maximum activity 248 
of the enzyme), AS is the absorbance obtained when the enzyme is inhibited by added 249 
peptides or positive control, and ASo is the absorbance of samples without enzyme. 250 
2.6. Resistance of peptides to simulated gastrointestinal digestion 251 
In vitro gastrointestinal digestion (GID) was carried out according to the method 252 
of Garrett et al. (1999) with slight modifications. Briefly, the pH of hydrolysates was 253 
adjusted with 1 M HCl to pH 2.0 followed by digestion with pepsin enzyme (1:35 254 
(w/w), enzyme: substrate ratio) at 37 °C with shaking for 1 h. Afterwards, the pH was 255 
adjusted to 5.0 with 0.1 M NaHCO3 and to 7.0–8.0 with 0.1 M NaOH and pancreatin 256 
enzyme (mixture of pancreatic proteases) was added at a 1:25 (w/w) enzyme:substrate 257 
ratio. The mixture was incubated by shaking at 37 °C and after 3 h, the digestion was 258 





































































2.7. Cell proliferation assay 261 
The MTT assay was employed to measure the cytotoxicity of peptides. The 262 
assay is based on the protocol described for the first time by Mosmann (1983). The 263 
assay was optimized for the human cell lines used in the experiments: HeLa (human 264 
cervical cancer cells), HT-29 (human colorectal adenocarcinoma cells), and HK-2 265 
(human renal proximal tubule cells). Culture medium was DMEN and it contained 266 
penicillin-streptomycin-amphotericin and 10% fetal bovine serum. Cell culture medium 267 
incorporated phenol red to control pH and was kept at 37 ºC in a humidified atmosphere 268 
with 5% CO2 until use. Three days after seeding, cells were placed in 24-well plates (at 269 
a density of 10,000 cells/well) and incubated with 50 µL of peptide solution for 24 h (37 270 
ºC/5% CO2).  A MTT stock solution of 5 mg/mL in PB was prepared and stored at 2–8 271 
°C until its use. The MTT stock solution was added to every culture cell in a 1:10 (cell 272 
volume: MTT stock solution volume) ratio and incubated for 3 to 4 h. Afterwards, 273 
DMEM was removed and the formed formazan crystals were dissolved with 500 μL 274 
DMSO. Absorbance of formazan crystals was measured at a wavelength of 570 nm. 275 
Citotoxicity was expressed as the percentage of viability of cells treated with samples 276 
relative to the corresponding control.  277 
2.8. Identification of peptides by RP-HPLC-MS/MS 278 
 MS/MS detection was carried out in an Electrospray Quadrupole-Time-of-Flight 279 
(ESI-Q-TOF) series 6530 mass spectrometer coupled to a liquid chromatograph (model 280 
1100), both from Agilent Technologies. Peptide separation was carried out using an 281 
Ascentis Express Peptide ES-C18 (100 x 2.1 mm id, 2.7 μm particle size) column based 282 
on fused pore superficially porous particles using an Ascentis Express Peptide ES-C18 283 
(5 x 2.1 mm id, 2.7 μm particle size) as guard column. Mobile phases A and B consisted 284 




































































0.3 mL/min and the elution gradient was from 5 to 35% B in 35 min and from 35 to 286 
95% B in 2 min followed by a reversed gradient from 95 to 5% B in 2 min to reach the 287 
initial chromatographic conditions. The column temperature was 55 ºC and the injection 288 
volume was 15 μL. Detection by ESI-Q-TOF was performed in the positive ion mode 289 
using a mass range from 50 to 3000 m/z. The ESI Jet Stream source conditions were: 290 
capillary voltage, 3500 V; fragmentator voltage, 200 V; drying gas, 10 L/min and 300 291 
ºC; nebulizer pressure, 50 psig; sheath gas, 5.5 L/min and 250 ºC. MS/MS was carried 292 
out using Auto mode and collision induced dissociation was set at 4 V per each 100 Da 293 
Mw. Two Agilent compounds (HP0921 and purine), yielding ions at m/z 922.0098 and 294 
121.0509, respectively, were simultaneously introduced and used as internal standards 295 
throughout the analysis. PEAKS Studio software from Bioinformatics Solutions Inc. 296 
(Waterloo, Canada) was used for the treatment of MS/MS data and de novo sequencing 297 
of peptide. Identified peptides showed an average local confidence (ALC, expected 298 
percentage of correct amino acids in the peptide sequence) ≥ 90% and a good precursor 299 
fragmentation pattern. Identifications were carried out using two individual samples 300 
injected by duplicate. Peptide identifications were accepted if they appeared in two 301 
independent samples. Since it is not possible to differentiate I from L by MS due to their 302 
equal molecular masses, both isoforms were presented in the results. 303 
2.9. Statistical Analysis  304 
Statistical analysis was performed using Statgraphics Software Plus 5.1 305 
(Statpoint Technologies, Inc., Warranton, VA, USA). Data comparison was carried out 306 
by the analysis of variance (ANOVA) or the test-t. The level of significant was set at P 307 





































































3. Results and discussion 310 
 The identification of lipid-lowering peptides has been scarcely performed or 311 
done using low selectivity and sensitivity techniques or conditions that have resulted in 312 
a scarce number of identified peptides. This work describes the optimization of a 313 
sensitive and selective method for the reliable identification of novel peptides with 314 
lipid-lowering capacity from a olive byproduct. 315 
 Figures 1A-D show the capacity of peptides from a hydrolysate of olive seeds 316 
proteins (obtained from a Manzanilla variety) to reduce exogenous lipid absorption by 317 
different mechanisms along with the peptide concentration (Figure 1E). The signals 318 
corresponding to the positive controls used in every assay (cholestyramine, β-sitosterol, 319 
simvastatin, and rutin) at concentrations identical to the peptide concentration in the 320 
hydrolysate (3.1 mg/mL, see Figure 1E) where included in Figures 1A-D. Capacity of 321 
peptides to reduce micellar cholesterol solubility was higher than the observed 322 
previously for peptides obtained from the Picual olive seed (García, González-García, 323 
Vásquez-Villanueva, & Marina, 2016). Main mechanism to reduce lipid absorption 324 
seemed to be the inhibition of the pancreatic lipase enzyme (70% of inhibition) while it 325 
did not show any capacity to sequester bile acids (glycodeoxycholic acid, taurocholic 326 
acid, and taurodeoxycholic acid). The capacity of peptides to inhibit cholesterol esterase 327 
and lipase enzymes ranged from 70-85% of the capacity of positive controls 328 
(simvastatin and rutin, respectively) while the capacity to reduce the micellar 329 
cholesterol solubility was higher than the observed for the positive control 330 
(cholestyramine). In comparison with bibliographic results (Rho, Park, Ahn, Shin, & 331 
Lee, 2007; Yust, Millán-Linares, Alcaide-Hidalgo, Milán, & Pedroche, 2012; 332 
Adisakwattana, Intrawangso, Hemrid, Chanathong, & Mäkynen, 2012; Jeon & Imm, 333 




































































to isolate and identify those peptides responsible of this activity, fractionation of 335 
peptides was carried out. 336 
3.1. Isolation of highly hypolipidemic peptides 337 
 Peptides were firstly separated in three fractions by ultrafiltration: fraction with 338 
peptides with Mw above 5 kDa, fraction with peptides with Mw between 5 and 3 kDa, 339 
and fraction with peptides with Mw below 3 kDa. Figures 1A-D show the 340 
hypolipidemic activity and peptide concentration of these fractions. Signals 341 
corresponding to the positive controls at concentrations identical to the peptide 342 
concentration in every fraction (fraction with peptides > 5 kDa, 0.4 mg/mL; fraction 343 
with peptides from 3-5 kDa, 0.3 mg/mL; fraction with peptides < 3 kDa, 2.4 mg/mL, 344 
see Figure 1E) were also graphed. Highest peptide concentration was observed in the 345 
fraction below 3 kDa. Fraction with peptides with Mw > 5 kDa showed a similar 346 
capacity to reduce the micellar cholesterol solubility to the observed for the whole 347 
hydrolysate but much higher than the obtained with the other two fractions (P < 0.05). 348 
Taurodeoxycholic bile acid binding capacity of fraction with peptides > 5 kDa was 349 
significantly higher than the obtained for the whole hydrolysate and for the other two 350 
fractions (P < 0.05). Moreover, this fraction showed a similar capacity to inhibit the 351 
cholesterol esterase enzyme to the observed for the whole hydrolysate and fractions (P 352 
< 0.05). Regarding the pancreatic lipase inhibition, the fraction with peptides > 5 kDa 353 
showed slightly lower capacity than the observed for the whole hydrolysate and the 354 
fraction with peptides < 3 kDa. Furthermore, the fraction with peptides > 5 kDa yielded 355 
a significant hypolipidemic activity in comparison with positive controls cholestyramine 356 
and simvastatin (at identical concentrations) and a similar hypolipidemic activity in 357 
comparison with positive controls β-sitosterol and rutin (at identical concentrations) (P 358 




































































and its peptide concentration, it was selected for its further fractionation by 360 
semipreparative RP-HPLC. 361 
 Different elution gradients were tried for the separation of peptides by 362 
semipreparative RP-HPLC and, finally, a gradient from 25 to 54% B in 45 min was 363 
selected. Figure 2A shows the chromatogram obtained. Nine fractions (F1-F9) were 364 
collected observing main signals in the fraction F3. Peptides in the nine fractions were 365 
characterized by measuring the same previous parameters and results are shown in 366 
Figures 2B-2E. No capacity to sequester bile acids was observed in any 367 
chromatographic fraction despite the fraction with peptides > 5 kDa did show certain 368 
ability to bind bile acids (see Figure 1B). The highest capacity to reduce the micellar 369 
cholesterol solubility was observed in fraction F3 (fraction showing main 370 
chromatographic peaks) while no capacity was observed for fractions F1, F2, F7, F8, 371 
and F9. Morever, the capacity observed for fraction F3 was statistically similar to the 372 
observed in the whole hydrolysate and in the fraction with peptides > 5 kDa (P > 0.05) 373 
(showed in Figure 1A) although peptide concentration was much lower. Pancreatic 374 
cholesterol esterase inhibition was significantly high in fraction F8 (P > 0.05) and 375 
below to 10 % in fractions F1, F2, F3, F4, F5, and F9. In fact, fraction F8 yielded a 376 
similar capacity to inhibit pancreatic cholesterol esterase to the observed for the fraction 377 
with peptides > 5 kDa and higher than the observed for the whole hydrolysate (shown in 378 
Figure 1C), although peptide concentration was much lower. Comparison of the activity 379 
of these fractions with that of positive control simvastatin (1.13 ± 0.81%), at the same 380 
concentration (0.1 mg/ mL), revealed that peptides in these fractions were highly active. 381 
Inhibition of pancreatic lipase activity was higher in fraction F5 followed by fractions 382 
F7 and F4. Activity in fraction F5 was slightly lower than in the whole hydrolysate and 383 




































































in fraction F3 was also 60 and 10 times lower than in the whole hydrolysate and in the 385 
fraction with peptides > 5 kDa, respectively. The highest peptide contents were 386 
observed in fractions F1, F2, F3, and F4. Since there was no fraction yielding the 387 
greatest activity in all assays, it was not possible to select a single fraction but it was 388 
possible to select fractions F3, F4, F5, F6, F7, and F8 as most favorable.  389 
 Moreover, since lipid-lowering capacity could be altered during gastrointestinal 390 
digestion, this activity was next evaluated in the peptides obtained when submitting 391 
selected fractions (F3, F4, F5, F6, F7 and F8) to a simulated gastrointestinal digestion. 392 
Figures 3 A-C show the capacity to reduce the micellar cholesterol solubility and to 393 
inhibit the pancreatic cholesterol esterase and pancreatic lipase enzymes of the selected 394 
fractions. In comparison with results showed in Figure 2, the capacity to reduce micellar 395 
cholesterol solubility significantly decreased when peptides were submitted to 396 
gastrointestinal digestion (except in fractions F7 and F8). However, gastrointestinal 397 
digestion of peptides resulted in an increase in the capacity to inhibit the activity of the 398 
cholesterol esterase enzyme (in comparison with results showed in Figure 2) observing 399 
the highest inhibition in fractions F3 and F6. Fractions showed, in general, a decrease in 400 
the capacity to inhibit pancreatic lipase enzyme (comparing with Figure 2) observing 401 
the highest activity in fraction F7 followed by fraction F3 (in this case, there was no 402 
significant difference between the capacity observed after and before gastrointestinal 403 
digestion). Since fraction F3 showed the highest capacity to reduce the micellar 404 
cholesterol solubility and to inhibit pancreatic cholesterol esterase enzyme and the 405 
second highest capacity to inhibit pancreatic lipase enzyme, it was considered the most 406 
suitable fraction in terms of hypolipidemic capacity. Comparing fraction F3 (Figure 2) 407 
with the fraction with peptides > 5 kDa (Figure 1), it was observed that starting fraction 408 




































































fraction F3 and a similar capacity to reduce micellar cholesterol solubility, but fraction 410 
> 5 kDa also showed more than twice the peptide content than fraction F3. In 411 
comparison with the whole hydrolysate, fraction F3 showed a similar capacity to reduce 412 
micellar cholesterol solubility and a lower capacity to inhibit cholesterol esterase and 413 
pancreatic lipase enzymes but the whole hydrolysate was also 18 times more 414 
concentrated than fraction F3. Moreover, safety of peptides in fraction F3 was 415 
demonstrated by assessing cell viability of different human cell lines (one healthy cell 416 
line (HK-2) and two cancer cell lines (HeLa and HT-29)) treated with these peptides.  417 
3.2. Optimization of a method for the identification of hypolipidemic peptides using high 418 
resolution RP-HPLC-MS/MS 419 
 Peptides in the fraction F3 were firstly analyzed by high resolution RP-HPLC-420 
ESI-Q-TOF using a gradient from 5 to 95% B (ACN + 0.3% (v/v) AA) in 37 min. 421 
Although the number of identified peptides ranged from 9-15 peptides in four replicates, 422 
only five peptides were identified in all of them. In order to avoid potential signal 423 
suppression and to identify the highest number of peptides with reliability, the following 424 
parameters were next optimized: sample dilution, elution gradient, and collision energy. 425 
Rest of MS parameters (fragmentator voltage; nebuliser pressure; capillary voltage; gas 426 
temperature; gas flow; skimmer; sheath gas flow and temperature) were fixed based on 427 
knowledge of our reseach team and on previous results that demonstrated that these 428 
conditions were suitable to avoid source spontaneous fragmentation of peptides and to 429 
obatin a sensitive detection of peptides (Puchalska, García, & Marina, 2013). Sample 430 
was injected at three different concentrations (no dilution, dilution 1:3, and dilution 431 
1:10) to find out whether sample concentration could affect the number of identified 432 
peptides. Dilution 1:3 enabled to increase the number of identified peptides from 5 to 9 433 




































































(3 peptides). From this results, sample was diluted 1:3 times before its analysis. Next, 435 
the elution gradient was modified for the better separation of peptides and for avoiding 436 
potential signal supression. Figure 4 shows the separations obtained using three assayed 437 
elution gradients observing a better separation with the gradient from 5-35% B in 35 438 
min. Collision energy was also optimized using 4, 5, 6, and 7 V/100 Da Mw. Increasing 439 
collision energy resulted in a significant reduction in the number of identified peptides 440 
and a collision energy of 4 V was selected. 441 
3.3. Identification of peptides in fraction F3 by RP-HPLC-ESI-Q-TOF-MS/MS 442 
 Peptides in fraction F3 obtained by semipreparative RP-HPLC were sequenced 443 
by RP-HPLC-ESI-Q-TOF-MS/MS using optimized conditions. Figure 5 shows the TIC 444 
(Total Ion Chromatogram) corresponding to this fraction and the fragmentation spectra 445 
obtained for two peptides (EELVE and DYNDDQF) detected at 7.7 and 8.9 min, 446 
respectively. Despite many peptides could be detected, only those with ALC higher than 447 
90% and appearing in two independent samples were selected. Table 1 shows the 448 
sequences of identified peptides together with the ALC, the retention time, the 449 
molecular mass, the mass accuracy (expressed in ppm), and isoelectric point. Peptides 450 
could not be traced to any protein since they had not been sequenced yet. Ten different 451 
peptides were identified, most of them showing Mw below 1 kDa and monocharged. 452 
Mw were much lower than expected but it could be explained by the poor selectivity of 453 
ultrafiltration filters, especially at low Mw (Puchalska, García, & Marina, 2014). Most 454 
peptides eluted in the first half of the chomatogram. Peptides presented between 4-9 455 
amino acids, very acidic isoelectric points (Ip), and a good solubility in water (obtained 456 
using Innovagen's peptide property calculator). A high amount (52%) of acidic amino 457 
acids (aspartic acid (D) and glutamic acid (E)) and their amides (asparagine (N) and 458 




































































Surprisingly, these amino acids were also present in other peptides yielding lipid-460 
lowering capacity (Zhang, Yokoyama, & Zhang, 2012; Nagaoka, 2001) and their 461 
presence could be a common feature among hypolipidemic peptides. All identified 462 
peptides were checked against BIOPEP database but they had not been detected before. 463 
Specially interesting is peptide FDGEVEK since Nagaoka et al. (2001) identified a 464 
hypocholesterolemic peptide from a milk β-lactoglobulin tryptic hydrolysate with the 465 





































































4. Conclusions 468 
 Ten different peptides with lipid-lowering capacity have been isolated by 469 
semipreparative RP-HPLC and identified by an optimized RP-HPLC-ESI-QTOF 470 
method from olive seed proteins. Peptides showed a multifunctional character since 471 
they could simultaneously fight hyperlipidemia by different pathways: reduction of 472 
micellar cholesterol solubility, inhibition of cholesterol esterase enzyme, and inhibition 473 
of lipase enzymes. Most active peptides remained in the fraction with Mw higher than 5 474 
kDa. Semipreparative RP-HPLC enabled to obtain one fraction, fraction F3, that 475 
grouped peptides showing a high lipid-lowering capacity, even after gastrointestinal 476 
digestion. Peptides concentrated in this fraction presented a high amount of glutamic 477 
acid and aspartic acid and their amides, glutamine and asparagine, which could be a 478 
common feature among hypolipidemic peptides. This is the first reliable identification 479 
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Figure captions 589 
Figure 1. Capacity to reduce micellar cholesterol solubility (A), to bind bile acids (B),  590 
and to inhibit pancreatic cholesterol esterase (C) and pancreatic lipase (D) enzymes of 591 
the whole olive seed hydrolysate, fractions obtained by ultrafiltration (> 5 kDa, 3-5 592 
kDa, and < 3 kDa), and positive controls (cholestyramine, -sitosterol, simvastatin, and 593 
rutin) used in every assay at concentrations identical to the peptide concentrations in 594 
whole hydrolysate and fractions (E). Values are expressed as mean ± standard deviation. 595 
Significant differences among whole hydrolysate and fractions in every assay, obtained 596 
by ANOVA, are indicated by a letter (a-d).  597 
Figure 2. Separation by semipreparative RP-HPLC of peptides in fraction with peptides 598 
> 5 kDa (A) and capacity to reduce micellar cholesterol solubility (B), to inhibit 599 
pancreatic cholesterol esterase (C) and pancreatic lipase enzymes (D), and peptide 600 
content (E) of chromatographic fractions. Values are expressed as mean ± standard 601 
deviation. Significant differences among fractions in every assay, obtained by ANOVA, 602 
are indicated by a letter (a-f). 603 
Figure 3. Capacity to reduce micellar cholesterol solubility (A) and to inhibit the 604 
activity of pancreatic cholesterol esterase (B) and pancreatic lipase (C) enzymes of 605 
fractions F3, F4, F5, F6, F7, and F8 obtained by semipreparative RP-HPLC after a 606 
simulated gastrointestinal digestion. Values are expressed as mean ± standard deviation. 607 
Significant differences among fractions in every assay, obtained by ANOVA, are 608 
indicated by a letter (a-d). 609 
Figure 4.  TIC corresponding to the separation of peptides in fraction F3 by RP-HPLC-610 




































































Figure 5. Total ion chromatogram (TIC) obtained by RP-HPLC-ESI-Q-TOF for the 612 

























Table 1. Peptide sequence, average local confidence (ALC), retention time (RT), molecular mass, mass accuracy (ppm), and isoelectric point of 
peptides sequenced in fraction F3. 
Peptide sequence ALC (%) RT (min) Mass (Da) ppm Isoelectric point** 
EELVE/EEIVE* 97 7.7 617.2908 7.7 0.76 
DYNDDQF 96 11.8 915.3246 8.9 0.53 
SAEDME 95 2.6 680.2323 5.6 0.66 
YNDGFE 95 9.7 743.2762 7.7 0.71 
AVFDDTLQE/AVFDDTIQE* 95 16.9 1036.4712 9.4 0.59 
NVDLE/NVDIE 94 8.7 588.2755 6.8 0.71 
ESGGVTE 94 2.2 677.2868 9.8 0.85 
FDDTLEQ/FDDTIEQ* 93 13.2 866.3658 8.8 0.58 
EMEE 93 1.8 536.1788 7.8 0.76 
FDGEVEK 91 7.8 822.3759 6.8 3.69 
  * Since it is not possible to differentiate I from L due to their equal molecular masses, both sequences have been included in the table. 
  ** Determined using Innovagen's peptide property calculator 
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